Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

634
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
634
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

558
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
558

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Practical Guide to Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology and therapy·2026
Same author

Sporadic Creutzfeldt-Jakob disease following venison exposure in a chronic wasting disease-endemic region: a zoonotic surveillance perspective.

Frontiers in public health·2026
Same author

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada.

European journal of human genetics : EJHG·2026
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Polyneuropathy in p.V142I hereditary transthyretin amyloidosis: Diagnostic challenges and clinical considerations.

Journal of the neurological sciences·2026
Same author

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026

Related Experiment Video

Updated: Dec 8, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.4K

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.

Jeremy M Shefner1, Jinsy A Andrews2, Angela Genge3

  • 1Barrow Neurological Institute, Phoenix, AZ, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|September 24, 2020
PubMed
Summary

Reldesemtiv showed trends toward benefit in patients with amyotrophic lateral sclerosis (ALS), despite not reaching statistical significance in the primary endpoint. Further Phase 3 trials are recommended to assess its efficacy and safety in ALS treatment.

Keywords:
Randomized clinical trialamyotrophic lateral sclerosisreldesemtiv

More Related Videos

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.5K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.3K

Related Experiment Videos

Last Updated: Dec 8, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.4K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.5K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.3K

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
  • Current treatments for ALS offer limited efficacy.
  • Reldesemtiv is an investigational drug targeting muscle function in ALS.

Purpose of the Study:

  • To evaluate the safety, dose response, and preliminary efficacy of reldesemtiv in ALS patients.
  • To assess changes in respiratory function and functional scores over a 12-week treatment period.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 458 patients with ALS.
  • Patients received reldesemtiv (150, 300, or 450 mg twice daily) or placebo for 12 weeks.
  • Primary endpoint: change in percent predicted slow upright vital capacity (SVC); secondary endpoints included ALSFRS-R and muscle strength.

Main Results:

  • The primary efficacy analysis did not achieve statistical significance (p=0.11).
  • Secondary endpoints also showed no statistically significant effects (ALSFRS-R, p=0.09; muscle strength, p=0.31).
  • Post hoc analyses indicated trends favoring reldesemtiv across all endpoints, with some nominal significance (e.g., ALSFRS-R, p=0.01).

Conclusions:

  • Reldesemtiv demonstrated a favorable safety profile, with reversible hepatic and renal abnormalities.
  • While not statistically significant, trends suggested potential clinical benefit in ALS patients.
  • A pivotal Phase 3 trial is warranted to further evaluate reldesemtiv's impact on ALS progression.